Priya Mande
Chief Executive Officer RNAvate
Priya Mande is Chief Executive Officer of RNAvate, focused on the development of novel circular RNA therapeutics out of the Molecular Research Laboratories (MRC), in Cambridge UK.
Priya was previously a founding member of PsiOxus Therapeutics, a member of the UK Government Covid-19 Vaccine Taskforce and a Vaccine Project Leader at Pfizer. Priya has a wealth of experience in transforming academic spin outs to award winning companies through raising capital, establishing & leading high performing teams, deal making and creating shareholder & patient centric value.
Seminars
Tuesday 21st July 2026
CEO & mRNA Leaders Think Tank: From CAR-T Platforms, Gene Editing Triumphs & Cancer Immunotherapy Clinical Advances; Navigating mRNA’s Potential into New Therapies & Tools Towards Better Drugs for Patients Faster
9:00 am
- What are the future opportunities, promising targets and applications on the horizon for mRNA to achieve commercial success?
- How are recent mRNA and LNP platform acquisitions fueling next generation innovations from science to strategy?
- Linear, circular, self-amplifying, trans-amplifying RNA – Which modality offers the most efficiency?
- With clinical trials moving towards the far East and Australia, what opportunities does this open for the mRNA industry to progress faster to clinical validation?
Wednesday 22nd July 2026
Circular RNA: From Promise to Reality
12:00 pm
- Designing next-generation Circular RNA
- Delineating the challenges of developing a circular RNA platform
- Highlighting the implications for the pipeline and opportunities for the circular RNA field
